Context Therapeutics Inc.
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
CNTX$0.20+3.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| ExhibitNo. | Exhibit Description |
| 3.1 | Amended & Restated Certificate of Incorporation of Context Therapeutics Inc. as amended through March 11, 2026 (incorporated by reference to Exhibit 3.1 to the Company's Annual Report on Form 10-K (File No. 001-40654), as filed with the SEC on March 23, 2026). |
| 3.2 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation, dated June 24, 2026 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-40654), as filed with the SEC on June 26, 2026). |
| 3.3 | Amended and Restated Bylaws of Context Therapeutics Inc. (incorporated by reference to Exhibit 3.2 to the Company's Annual Report on Form 10-K (File No. 001-40654), as filed with the SEC on March 21, 2024). |
| 10.1*† | Amendment No. 1, dated August 4, 2026, to that certain Amended and Restated Employment Agreement, dated October 22, 2021, between Context Therapeutics Inc. and Martin Lehr. |
| 10.2*† | Amendment No. 1, dated August 4, 2026, to that certain Employment Agreement, dated November 1, 2021, between Context Therapeutics Inc. and Jennifer Minai-Azary. |
| 10.3*† | Amendment No. 1, dated August 4, 2026, to that certain Employment Agreement, dated October 22, 2021, between Context Therapeutics Inc. and Alex Levit. |
| 10.4*† | Amendment No. 1, dated August 4, 2026, to that certain Employment Agreement, dated June 9, 2025, between Context Therapeutics Inc. and Karen Chagin, M.D. |
| 10.5# | First Amendment to License Agreement, dated May 14, 2026, by and between the Company and BioAtla, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-40654), as filed with the SEC on May 18, 2026). |
| 31.1* | Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Exchange Act. |
| 31.2* | Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Exchange Act. |
| 32.1+ | Certification Pursuant to 18 U.S.C. Section 1350 of principal executive officer and principal financial officer. |
| 101* | The following portions of Context Therapeutics Inc.’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets; (ii) Condensed Consolidated Statements of Operations; (iii) Condensed Consolidated Statements of Changes in Stockholders’ Equity; (iv) Condensed Consolidated Statements of Cash Flows; (v) Notes to the Unaudited Condensed Consolidated Financial Statements; and (vi) the information under Part II, Item 5, "Other Information." |
| 104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101 hereto) |
*Filed herewith
†Management contract or compensatory plan
Certain schedules to this agreement have been omitted in accordance with Item 601(a)(5) of Regulation S-K. A copy of any omitted schedules will be furnished supplementally to the SEC upon request.
- This certification is being furnished pursuant to 18 U.S.C. Section 1350 and is not being filed for purposes of Section 18 of the Exchange Act, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.